A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, non-randomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Gupta, Vikas, Mesa, Ruben A., Deininger, Michael W.N., Rivera, Candido E., Sirhan, Shireen, Brachmann, Carrie Baker, Collins, Helen, Kawashima, Jun, Xin, Yan, Verstovsek, Srdan
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2017
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5210237/
https://ncbi.nlm.nih.gov/pubmed/27634203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.148924
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires